RPTX

Repare Therapeutics Inc. (RPTX) ESG Analysis Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.8 (Moderate)

RPTX’s R&D intensity supports product innovation with a lower direct footprint than heavy industrial peers, but the metric alone does not evidence superior environmental management.

The company’s very low debt-to-equity suggests limited balance-sheet pressure for capital-intensive decarbonization, yet peers with disclosed climate targets still appear better positioned on transition readiness.

No emissions, energy, or waste disclosures were provided, so environmental assessment remains constrained versus peers that report these metrics and can demonstrate operational control.

Absent evidence of climate governance or resource-efficiency programs, RPTX appears broadly average rather than advantaged on the environmental factors most material over the next 2–5 years.

Social

Score:

Stock-based compensation at 0.51x revenue indicates meaningful employee alignment, but it also suggests heavier dilution pressure than peers with more restrained equity pay practices.

R&D spending can support workforce skill development and product safety, yet the available data do not show stronger labor, customer, or community outcomes than peers.

No disclosures were provided on turnover, safety, diversity, or human-capital management, leaving RPTX behind peers that can substantiate social performance with filed metrics.

Overall, the social profile looks middling because limited evidence of structured human-capital disclosure offsets the modest positive signal from innovation-linked spending.

Governance

Score:

Debt-to-equity of 0.003 implies conservative leverage and reduces creditor-driven governance stress, but peers with stronger disclosure standards still look better governed overall.

High stock-based compensation relative to revenue can align management with shareholders, yet it also raises pay-governance scrutiny versus peers with lower equity dilution.

R&D intensity may indicate disciplined capital allocation, but without board, audit, or control disclosures, governance quality cannot be judged as stronger than peers.

On the available evidence, RPTX shows some governance discipline through low leverage, but incomplete disclosure keeps it in the middle of the peer set.

Overall Score

Score:

RPTX appears broadly average versus peers because limited ESG disclosure and only partial positive signals prevent a stronger relative assessment.

Score Driver: Incomplete ESG Disclosure Is The Main Constraint On Relative Positioning Versus Peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Repare Therapeutics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →